Presentation is loading. Please wait.

Presentation is loading. Please wait.

A Review of the Committee Nomination and Review Process Nancy S. Green, MD Associate Dean for Clinical Research Operations Associate Professor of Clinical.

Published byClyde Boyd Modified over 9 years ago

Similar presentations

Presentation on theme: "A Review of the Committee Nomination and Review Process Nancy S. Green, MD Associate Dean for Clinical Research Operations Associate Professor of Clinical."— Presentation transcript:

1 A Review of the Committee Nomination and Review Process Nancy S. Green, MD Associate Dean for Clinical Research Operations Associate Professor of Clinical Pediatrics, Division of Hematology Associate Director, Irving Institute for Clinical Translational Research Columbia University Medical Center ACHDNC 8-7-08

2 ACHDNC Evidence Review Process: Overview Nomination Form HRSA Administrative Review Advisory Committee External Evidence Review Workgroup (ERW) Possible Recommendations: Universal NBS Targeted screening Pilot study Critical studies needed No recommendation Recommend against NBS Possible Further Study(ies ) Nomination Review and Prioritization Workgroup (NRPW)

3 ACHDNC Evidence Review Process: Subset Nomination Form HRSA Administrative Review Advisory Committee * External Evidence Review Workgroup (ERW) [Dr. Perrin] Nomination Review and Prioritization Workgroup (NRPW) An AC sub-group Task: Readiness for EBR? - Criteria - Recommendation to AC * Only the AC may make binding decisions An Independent group Tasks: Formal EBR - Define terms and criteria - EBR report Committee Chair Criteria Workgroup: - Nomination process and form

4 Nomination Review and Prioritization Workgroup: Is a Nominated Condition Ready for EBR? 1) The nominated condition(s) is medically serious. 2) Prospective pilot data (U.S. and/or international) from population-based assessment are available for this disorder. 3) The spectrum of this disorder is well described, to help predict the phenotypic range of those children who will be identified based on population-based NBS. 4) There is a screening test that is capable of identifying the condition. 5) If the spectrum of disease is broad, those who are most likely to benefit from treatment are identifiable, especially if treatment is onerous or risky. 6) There are defined treatment protocols, FDA approval/clearance (if applicable) and availability of treatment. Overall recommendation to the Advisory Committee by the NRPW: 2 options: Ready for EBR or Not Ready for EBR, with rationale

5 SCID – Ready for EBR – under review Pompe - Ready for EBR – under review Krabbe – Ready Fabry – Not ready Niemann Pick – NRPW review pending Nomination Review and Prioritization Workgroup: Nominated Conditions Considered to Date for EBR

Download ppt "A Review of the Committee Nomination and Review Process Nancy S. Green, MD Associate Dean for Clinical Research Operations Associate Professor of Clinical."

Similar presentations

Team/Organization Name Background and structure Location Brief system information (type, size) Pilot population.

Team/Organization Name Background and structure Location Brief system information (type, size) Pilot population.
1 Understanding How the U.S. Preventive Services Task Force Works USPSTF 101.

1 Understanding How the U.S. Preventive Services Task Force Works USPSTF 101.
Pulse-ox to Policy: The Story Behind Screening Newborns for Heart Defects Natasha Bonhomme Babys First Test, Genetic Alliance.

Pulse-ox to Policy: The Story Behind Screening Newborns for Heart Defects Natasha Bonhomme Babys First Test, Genetic Alliance.
Engaging Patients and Other Stakeholders in Clinical Research

Engaging Patients and Other Stakeholders in Clinical Research
Jolene Johnson, MD Associate Clinical Professor of Medicine, LSU School of Medicine Head, Statewide Diabetes Disease Management, LSU HCSD Diabetes Disease.

Jolene Johnson, MD Associate Clinical Professor of Medicine, LSU School of Medicine Head, Statewide Diabetes Disease Management, LSU HCSD Diabetes Disease.
Decision Criteria and Process Advisory Committee on Heritable Disorders in Newborns and Children February 26-27, 2009.

Decision Criteria and Process Advisory Committee on Heritable Disorders in Newborns and Children February 26-27, 2009.
SACHDNC Meeting January 26/27, 2012 Nomination and Prioritization Workgroup Report on 22q11.2 Deletion Syndrome (22q11.2DS; DiGeorge Syndrome, DGS-1) Dietrich.

SACHDNC Meeting January 26/27, 2012 Nomination and Prioritization Workgroup Report on 22q11.2 Deletion Syndrome (22q11.2DS; DiGeorge Syndrome, DGS-1) Dietrich.
NBSTRN Update NCC/RC PI/PD Meeting November 19, 2010 Michael Watson.

NBSTRN Update NCC/RC PI/PD Meeting November 19, 2010 Michael Watson.
Oncologic Drugs Advisory Committee September 6, 2006 ODAC and the FDA Arms-Length or Arm-In-Arm? Abigail Alliance for Better Access to Developmental Drugs.

Oncologic Drugs Advisory Committee September 6, 2006 ODAC and the FDA Arms-Length or Arm-In-Arm? Abigail Alliance for Better Access to Developmental Drugs.
Nomination and Prioritization Reports: MPS I and Pompe Disease Nancy S. Green, MD Associate Dean for Clinical Research Operations Associate Professor of.

Nomination and Prioritization Reports: MPS I and Pompe Disease Nancy S. Green, MD Associate Dean for Clinical Research Operations Associate Professor of.
Pediatric Ethics Subcommittee of Pediatric Advisory Committee, September 10, 2004 Analysis of Research Protocols Involving Children: Combining Subparts.

Pediatric Ethics Subcommittee of Pediatric Advisory Committee, September 10, 2004 Analysis of Research Protocols Involving Children: Combining Subparts.
Definition of a Consumer One that consumes, especially one that acquires goods or services for direct use or ownership rather than for resale or use in.

Definition of a Consumer One that consumes, especially one that acquires goods or services for direct use or ownership rather than for resale or use in.
 Lowell Smith Sr. Director, Business & Communication Research Administration Moffitt Cancer Center  Jeanine Stiles Chief Administrative Officer Associate.

 Lowell Smith Sr. Director, Business & Communication Research Administration Moffitt Cancer Center  Jeanine Stiles Chief Administrative Officer Associate.
Knowledge Update Clinical documentation: from preclinical studies to drug registration Split, 12 September 2008.

Knowledge Update Clinical documentation: from preclinical studies to drug registration Split, 12 September 2008.
Oncology Pediatric Initiatives Richard Pazdur, MD Director, Division of Oncology Drug Products.

Oncology Pediatric Initiatives Richard Pazdur, MD Director, Division of Oncology Drug Products.
Kathryn Camp, M.S., R.D., CSP Consultant to the Office of Dietary Supplements National Institutes of Health Secretary’s Advisory Committee on Heritable.

Kathryn Camp, M.S., R.D., CSP Consultant to the Office of Dietary Supplements National Institutes of Health Secretary’s Advisory Committee on Heritable.
Secretary’s Advisory Committee on Heritable Disorders of Newborns and Children September 22, 2011 Newborn Screening Translational Research Network (NBSTRN)

Secretary’s Advisory Committee on Heritable Disorders of Newborns and Children September 22, 2011 Newborn Screening Translational Research Network (NBSTRN)
Setting the Stage for Change Drafting Maine’s State Plan for Individuals with ASD Nancy Cronin, MA ASD Systems Change Initiative Coordinator.

Setting the Stage for Change Drafting Maine’s State Plan for Individuals with ASD Nancy Cronin, MA ASD Systems Change Initiative Coordinator.
TYPE 2 TRANSLATIONAL RESEARCH 2009 GRANT PROGRAMS UW Institute for Clinical and Translational Research (ICTR) Community-Academic Partnership Core (CAP)

TYPE 2 TRANSLATIONAL RESEARCH 2009 GRANT PROGRAMS UW Institute for Clinical and Translational Research (ICTR) Community-Academic Partnership Core (CAP)
Ethical Issues in Pediatric Research: Placebo controlled trials for gastoesophogeal reflux Benjamin Wilfond MD Medical Genetics Branch National Human Genome.

Ethical Issues in Pediatric Research: Placebo controlled trials for gastoesophogeal reflux Benjamin Wilfond MD Medical Genetics Branch National Human Genome.

Similar presentations

Ads by Google